CPP-115

CPP-115 is an experimental drug being studied for the treatment of various neurological and psychiatric disorders including cocaine addiction,[1] infantile spasms,[2][3] and Tourette syndrome.[4]

CPP-115
Legal status
Legal status
  • Investigational
Identifiers
  • (1S,3S)-3-Amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid
CAS Number
PubChem CID
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC7H9F2NO2
Molar mass177.151 g·mol−1

CPP-115 is a GABA aminotransferase (GABA-AT) inactivator.[1]

History

CPP-115 was discovered in the research laboratory of Richard B. Silverman, for which he received the E. B. Hershberg Award for Important Discoveries in Medicinally Active Substances.[5] It was licensed to Catalyst Pharmaceuticals for development in 2009.[6][7]

CPP-115 has been granted orphan drug status for the treatment of infantile spasms by the FDA and for the treatment of West syndrome by the European Commission.[8]

As of 2022, CPP-115 is in Phase II clinical trials for Tourette syndrome.[4]

References
  1. Pan Y, Gerasimov MR, Kvist T, Wellendorph P, Madsen KK, Pera E, et al. (January 2012). "(1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a potent γ-aminobutyric acid aminotransferase inactivator for the treatment of cocaine addiction". Journal of Medicinal Chemistry. 55 (1): 357–366. doi:10.1021/jm201231w. PMC 3257419. PMID 22128851.
  2. "Epilepsy Pipeline Tracker: CPP-115". epilepsy.com.
  3. Doumlele K, Conway E, Hedlund J, Tolete P, Devinsky O (2016). "A case report on the efficacy of vigabatrin analogue (1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115) in a patient with infantile spasms". Epilepsy & Behavior Case Reports. 6: 67–69. doi:10.1016/j.ebcr.2016.08.002. PMC 5024311. PMID 27668180.
  4. "CPP-115". Adis Insight.
  5. Silverman RB (January 2012). "The 2011 E. B. Hershberg award for important discoveries in medicinally active substances: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a GABA aminotransferase inactivator and new treatment for drug addiction and infantile spasms". Journal of Medicinal Chemistry. 55 (2): 567–575. doi:10.1021/jm201650r. PMC 3266980. PMID 22168767.
  6. Hawker DD, Silverman RB (October 2012). "Synthesis and evaluation of novel heteroaromatic substrates of GABA aminotransferase". Bioorganic & Medicinal Chemistry. 20 (19): 5763–5773. doi:10.1016/j.bmc.2012.08.009. PMC 3448830. PMID 22944334.
  7. Bandell B (August 31, 2009). "Catalyst Pharmaceutical signs licensing deal with Northwestern". South Florida Business Journal.
  8. "Catalyst Pharmaceuticals Expands Commercial Leadership Team" (Press release). Catalyst Pharmaceuticals.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.